These findings suggest that targeting ELK3 activation and its stability-enhancing pathways may offer effective therapeutic strategies to overcome docetaxel resistance in PCa, potentially improving the treatment of CRPC, warranting further investigation. Here, ELK3 is linked to posterior cortical atrophy.